Altimmune (ALT) Interest Expenses (2010 - 2026)

Altimmune (ALT) has reported Interest Expenses for 17 consecutive years, with $2.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses rose 7.19% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $2.7 million (up 7.19% YoY), while the FY2025 annual figure was $2.9 million, down 97.27% from the prior year.
• Interest Expenses improved to $2.7 million in Q1 2026 per ALT's latest filing, from $1.1 million in the prior quarter.
• Across five years, Interest Expenses topped out at $15.1 million in Q1 2024 and bottomed at -$183000.0 in Q4 2022.
• Historically, Interest Expenses has averaged $2.1 million across 5 years, with a median of $726000.0 in 2023.
• Annual changes were most pronounced in 2022 — Interest Expenses plunged 99.62% — and 2025, when it jumped 113900.0%.
• Altimmune's Interest Expenses stood at -$183000.0 in 2022, then surged by 101.09% to $2000.0 in 2023, then slumped by 50.0% to $1000.0 in 2024, then surged by 113900.0% to $1.1 million in 2025, then surged by 135.35% to $2.7 million in 2026.
• Business Quant data shows ALT's Interest Expenses at $2.7 million in Q1 2026, $1.1 million in Q4 2025, and $1.5 million in Q3 2025.